Clinical Trial Update: Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease [Phase 2]

View source ↗

Summary

Phase 2 trial comparing a glycopyrrolate/formoterol fumarate metered-dose inhaler to Spiriva as an active control in moderate-to-severe COPD; the study has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Glycopyrrolate/Formoterol Fumarate MDI
• Spiriva (tiotropium)

Snippet

Sponsor: Pearl Therapeutics, Inc. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED | Results posted: 2016-06-30